新中国成立70周年以来药品价格法律监管:历史回眸、现状检视与未来方向
|
摘要
新中国成立70周年来,我国市场对药品价格的决定作用得以明确,初步建立了药品价格法律监管体制、药品集中招标采购机制和药品价格行政执法队伍。但新时代药品价格法律监管领域仍存在监管法律体系不完善、现有定价机制不合理、市场流通监管乏力连同药价监管权力寻租等亟待解决的问题。建议我国坚持适度干预、社会本位和依法监管的法治理念,通过完善药品价格监管法律、探索药品合理定价机制、加强药品市场流通行政监管及限缩药价监管权力寻租空间,从而为更好地落实健康中国理念提供法治保障。
Since the founding of the People's Republic of China, the market has played a decisive role in determining drug prices.The drug price legal governance system, drug centralized bidding and procurement mechanism and drug price administrative team were set up. There were still some problems to be solved in the field of drug price legal supervision in the New Era, such as imperfect legal supervision system, unreasonable pricing mechanism, weak market circulation supervision and rent-seeking power of drug price supervision. It was suggested that China adhere to the rule of law concept of moderate intervention, social standard and law-based supervision, and provide legal backup for better implementation of the concept of Healthy China by improving drug price supervision laws, exploring reasonable drug pricing mechanism, strengthening administrative supervision of drug market circulation, and limiting and reducing drug price supervision power rent-seeking space.
Since the founding of the People's Republic of China, the market has played a decisive role in determining drug prices.The drug price legal governance system, drug centralized bidding and procurement mechanism and drug price administrative team were set up. There were still some problems to be solved in the field of drug price legal supervision in the New Era, such as imperfect legal supervision system, unreasonable pricing mechanism, weak market circulation supervision and rent-seeking power of drug price supervision. It was suggested that China adhere to the rule of law concept of moderate intervention, social standard and law-based supervision, and provide legal backup for better implementation of the concept of Healthy China by improving drug price supervision laws, exploring reasonable drug pricing mechanism, strengthening administrative supervision of drug market circulation, and limiting and reducing drug price supervision power rent-seeking space.
引文
[1]陈桂生,刘梦琦.基于利益博弈的药品价格规制问题研究[J].价格月刊,2018(5):7-14.
[2]刘万韬.我国药品价格形成机制及市场化改革路径研究[J].价格月刊,2017(1):45-50.
[3]俞平,朱菊艳,申俊龙.关于药品价格治理机制创新研究——纪念价格改革四十周年[J].价格理论与实践,2018(9):33-36.
[4]陈桂生,刘梦琦.基于利益博弈的药品价格规制问题研究[J].价格月刊,2018(5):7-14.
[5]向明.我国药品价格形成机制及市场化改革对策研究[J].价格月刊,2017(2):43-46.
[6]陈桂生,刘梦琦.基于利益博弈的药品价格规制问题研究[J].价格月刊,2018(5):7-14.
[7]郭莹,张惠玲,陈晶,等.日本药品价格政策研究及对我国的启示[J].中国药物经济学,2010(4):63-67.
[8]汪颢.影响我国药品价格因素的主成分分析[J].中国卫生经济,2018,37(8):71-73.
[9]闫晴.税务信息管理权与保护权的冲突与平衡[J].北京理工大学学报(社会科学版),2018,20(4):151-160.
[2]刘万韬.我国药品价格形成机制及市场化改革路径研究[J].价格月刊,2017(1):45-50.
[3]俞平,朱菊艳,申俊龙.关于药品价格治理机制创新研究——纪念价格改革四十周年[J].价格理论与实践,2018(9):33-36.
[4]陈桂生,刘梦琦.基于利益博弈的药品价格规制问题研究[J].价格月刊,2018(5):7-14.
[5]向明.我国药品价格形成机制及市场化改革对策研究[J].价格月刊,2017(2):43-46.
[6]陈桂生,刘梦琦.基于利益博弈的药品价格规制问题研究[J].价格月刊,2018(5):7-14.
[7]郭莹,张惠玲,陈晶,等.日本药品价格政策研究及对我国的启示[J].中国药物经济学,2010(4):63-67.
[8]汪颢.影响我国药品价格因素的主成分分析[J].中国卫生经济,2018,37(8):71-73.
[9]闫晴.税务信息管理权与保护权的冲突与平衡[J].北京理工大学学报(社会科学版),2018,20(4):151-160.